A STUDY ON COST ANALYSIS OF ORAL ANTIHYPERTENSIVE DRUGS AVAILABLE IN INDIA

Avanthi E*, Allen Joe Rodrigues, Anand Koppal, Abhishek Achar, Mahesh G K

ABSTRACT

The major health care problem in developing world is shifting from communicable diseases to non-communicable disease which causes morbidity more than mortality affecting the personal efficiency. Hypertension is a major health care burden in developing countries like India causing both morbidity and mortality. Few studies shows that the hypertension prevalence has raised from 2% to 15% in rural population and 2% to 25% in urban population in last six decades in India. This research work aims to enumerate the price of commonly available oral antihypertensive drugs in India. It also aims to study the cost variation of oral antihypertensive drugs. The present study was carried out in the department of Pharmacology in a tertiary care medical college in south India. The cost analysis of individual drugs by different manufacturers were done. Percentage of cost variation was analysed. The variation in cost of most of the antihypertensive drugs is more than 100%. It’s found maximum in Amlodipine (5mg) with cost variation of 625%, Atenolol 100 mg with cost variation of 413%. In India there is a wide price variation among antihypertensive drugs. The major gap in the cost variation of antihypertensive drugs to be narrowed for the benefit of the patients. So the government and the prescribing doctors should think about the huge difference in cost and work in the direction of benefitting the patient.

INTRODUCTION

The major health care problem in developing world is shifting from communicable diseases to non-communicable disease which causes morbidity more than mortality affecting the personal efficiency.

Non communicable diseases like hypertension and diabetes mellitus is posing major threat to well-being of the population. Hypertension is a major health care burden in developing countries like India causing both morbidity and mortality. Few studies shows that the hypertension prevalence has raised from 2% to 15% in rural population and 2% to 25% in urban population in last six decades in India [1].

Hypertension may lead to stroke, ischemic heart disease, renal failure. These complications can be prevented by efficient and...
judicious use of available pharmacological and non-pharmacological modes of management. The majority of the patients can be managed by common available antihypertensive drugs like Calcium channel blockers (CCB), Angiotension Converting Enzymes (ACE) inhibitors, β– Adrenergic blockers, Angiotensin antagonist, vasodilators, α– adrenergic blockers and centrally acting sympatholytic agents [2, 3].

The efficient management of hypertension is need of the hour to prevent morbidity and mortality. Even though many antihypertensive drugs are available in India the cost factor pose a major hindrance to its usage. It poses a major burden in low socio economic patients which sometimes may lead to psychological disturbance of the patient [4, 5].

With introduction of generic drugs in India the cost factor for antihypertensive drugs is no longer a major issue. But the patient’s acceptability for it is still a question [6, 7, 8].

The present study is carried out to analyse the cost effectiveness of different pharmaceutical products available in India for the management of Hypertension. It will provide information to the patient about the variations in the cost of a drugs with different manufacturers and helps cost effective choosing of drugs leading to better socioeconomic compliance [9, 10].

The aim of this work is to enumerate the price of commonly available oral antihypertensive drugs in India and study the cost variation of oral antihypertensive drugs

**MATERIAL AND METHODS**
The present study was carried out in the department of Pharmacology in a tertiary care medical college in south India. The list of commonly used oral antihypertensive drugs was made and the cost of the same by different manufacturers in different strength and combinations were obtained from “Current Index of Medical Specialties” and “Indian Drug Review” (IDR) .The cost of drugs was also crosschecked at pharmacy or retail drug store. 

Cost ratio between the maximum and minimum cost of the same drug manufactured by different pharmaceutical companies was calculated as follows:

\[
Cost\ ratio = \frac{Maximum\ cost}{Minimum\ cost}
\]

Percentage cost variation was calculated as follows

\[
Cost\ ratio = \frac{Maximum\ cost - Minimum\ cost}{Minimum\ cost} \times 100
\]

The cost variation is analysed with SPSS software 2.0 version with tools of median and interquartile range

**RESULTS**
The cost of different antihypertensive drugs were analysed and minimum and maximum cost of the drugs in a particular dosage are tabulated. The cost variation is analysed with SPSS software 2.0 version with tools of median and interquartile range

The variation in cost of most of the antihypertensive drugs is more than 100%. It’s found maximum in Amlodipine (5mg) with cost variation of 625%, Atenolol 100 mg with cost variation of 413%.

**DISCUSSION**
India is a developing country where most of the people are socioeconomically backward. Lack of awareness about the long term complications of hypertension as well as price factor of drugs make them compromise for the treatment [8, 9].

Though lot of manufacturers are there for antihypertensive drugs the variations in the price of drugs puts the patient in dilemma. Choosing an appropriate manufacturer with cost effective pricing is very much needed for proper management of the disease without compromising their daily basic needs [10].

As India predominantly has a branded generic market, 60,000 to 70,000 pharmaceutical products are available in the market [10]. Hence there is wide range of variation in price is seen.

A very few studies are available in Indian scenario to analyse the cost effectiveness of drugs. Antihypertensive drugs which are commonly used drugs in middle and old aged people pose a major cost burden. The variation in cost of most of the antihypertensive drugs is more than 100% in our study which is found to be similar to many studies carried out in India.

Our study may act as an eye opener for both manufacturers and consumers regarding the wide variation in the cost of same drug.
Figure 1: Cost variation analysis of commonly used antihypertensive drugs

Table 1: Cost analysis of common antihypertensive drugs

| S. No | Drug Name | Dose  | Maximum Cost (Inr) | Minimum Cost (Inr) | Cost Variation (%) | Cost Ratio |
|-------|-----------|-------|--------------------|--------------------|-------------------|------------|
| **ACE Inhibitors** | | | | | | |
| 1. | T. Enalopril | 2.5 mg | 30.23 | 6.00 | 403.2 | 5.03 |
| | | 5 mg | 51.34 | 12.23 | 319.7 | 4.1 |
| | | 10 mg | 100.20 | 32 | 213.2 | 3.1 |
| 2. | T. Lisnopril | 2.5 mg | 51.5 | 14.2 | 262.2 | 3.6 |
| | | 5 mg | 102 | 28 | 264.2 | 3.6 |
| | | 10 mg | 120.4 | 53.2 | 126.3 | 2.3 |
| 3. | T. Ramipril | 1.25 mg | 35.2 | 12.50 | 181.6 | 2.8 |
| | | 2.5 mg | 59.2 | 27 | 119.2 | 2.1 |
| | | 5 mg | 100.2 | 52 | 92.6 | 1.9 |
| | | 10 mg | 143.1 | 78.6 | 82.06 | 1.8 |
| 4. | T. Perindopril | 2 mg | 120 | - | N/A | N/A |
| | | 5 mg | 134 | - | N/A | N/A |
| | | 10 mg | 187 | - | N/A | N/A |
| S. No | Drug Name         | Dose  | Maximum Cost (Inr) | Minimum Cost (Inr) | Cost Variation (%) | Cost Ratio |
|-------|-------------------|-------|--------------------|--------------------|--------------------|------------|
|       | Angiotensin antagonist |       |                    |                    |                    |            |
| 5.    | T. Losartan       | 25mg  | 45.4               | 18.2               | 149.4              | 2.4        |
|       |                   | 50mg  | 88.9               | 30.3               | 193.3              | 2.9        |
| 6.    | T. Candesartan    | 4 mg  | 38.5               | 29.6               | 30.8               | 1.45       |
|       |                   | 8 mg  | 64.2               | 47.3               | 36.3               | 1.3        |
| 7.    | T. Olmesartan     | 20mg  | 184.2              | 45                 | 309.3              | 4.1        |
|       |                   | 40mg  | 168                | 58                 | 189.6              | 2.8        |
| 8.    | T. Telmisartan    | 20mg  | 45                 | 29.2               | 54.1               | 1.5        |
|       |                   | 40mg  | 86                 | 29                 | 196.7              | 2.9        |
|       |                   | 80mg  | 121                | 79.5               | 52.2               | 1.5        |
|       | Calcium channel blockers |   |                    |                    |                    |            |
| 9.    | T. Nifedipine     | 5 mg  | 11.3               | 10.9               | 3.6                | 1.09       |
|       |                   | 10mg  | 20.4               | 14.4               | 41.6               | 1.4        |
|       |                   | 20mg  | 32.1               | 19                 | 68.9               | 1.6        |
| 10.   | T. Felodipine     | 2.5 mg| 24                 | -                  | N/A                | N/A        |
|       |                   | 5 mg  | 42                 | -                  | N/A                | N/A        |
|       |                   | 10mg  | 71                 | -                  | N/A                | N/A        |
| 11.   | T. Amlodipine     | 2.5 mg| 28.2               | 7.8                | 261.5              | 3.6        |
|       |                   | 5 mg  | 74                 | 10.2               | 625.4              | 7.2        |
|       |                   | 10mg  | 54.2               | 32                 | 69.3               | 1.6        |
| 12.   | T. Cilnidipine    | 5 mg  | 50.4               | 23                 | 119.1              | 2.1        |
|       |                   | 10mg  | 82                 | 27                 | 203.7              | 3.03       |
|       |                   | 20mg  | 121                | 48.40              | 150                | 2.5        |
| 13.   | T. Diltiazam      | 30mg  | 24.4               | 16.7               | 46.1               | 1.46       |
|       |                   | 60mg  | 38.2               | 28.2               | 35.1               | 1.3        |
|       | β-blockers         |       |                    |                    |                    |            |
| 14.   | T. Atenolol       | 25mg  | 25.2               | 8.2                | 207.3              | 3.07       |
|       |                   | 50mg  | 24.3               | 5.9                | 310.1              | 4.11       |
|       |                   | 100mg | 35.4               | 6.98               | 413.0              | 5.1        |
| 15.   | T. Carvedilol     | 3.125mg| 31.2              | 8.9                | 250.5              | 3.5        |
|       |                   | 6.25 mg| 45.4              | 16.4               | 177.4              | 2.7        |
|       |                   | 12.5 mg| 78.5              | 29                 | 170.6              | 2.7        |
|       |                   | 25mg  | 124                | 56                 | 121.4              | 2.2        |
| 16.   | T. Labetolol      | 100mg | 135                | 116                | 16.3               | 1.16       |
| 17.   | T. Metoprolol     | 25mg  | 47.3               | 18.1               | 154.3              | 2.6        |
|       |                   | 50mg  | 65.4               | 30.10              | 117.2              | 2.1        |
| 18.   | T. Nebivolol      | 2.5 mg| 111.2              | 36.4               | 205.4              | 3.05       |
|       |                   | 5 mg  | 115.4              | 52.10              | 121.4              | 2.2        |
| 19.   | T. Propranolol    | 10mg  | 19                 | 7                  | 171.4              | 2.7        |
|       |                   | 20mg  | 23.4               | 17.4               | 40.2               | 1.5        |
|       |                   | 40mg  | 76.2               | 22.3               | 241.7              | 3.4        |
| S. No | Drug Name | Dose | Maximum Cost (Inr) | Minimum Cost (Inr) | Cost Variation (%) | Cost Ratio |
|-------|-----------|------|--------------------|--------------------|--------------------|------------|
| 20.   | T. Methyldopa | 250mg | 25.3              | 20.5              | 24.6             | 1.2        |
| 21.   | T. Prozion | 2.5 mg | 112.6                       | 75.8              | 48.9             | 1.4        |
|       |           | 5 mg | 122.4                      | 103.5             | 18.3             | 1.1        |
| 22.   | T. Cinnarizine | 25mg | 38.90                     | 15.5              | 150.9            | 2.5        |
|       |           | 75mg | 45.1                       | 31.0              | 45.4             | 1.4        |
| 23.   | T. Isoxsuprine | 10mg | 24.5                        | 13.9              | 76.2             | 1.7        |
|       |           | 20mg | 35.3                        | 26.7              | 32.3             | 1.3        |
|       |           | 40mg | 58.2                        | 46.3              | 25.7             | 1.2        |

**CONCLUSION**
In India there is a wide price variation among antihypertensive drugs. The major gap in the cost variation of antihypertensive drugs to be narrowed for the benefit of the patients. So the government and the prescribing doctors should think about the huge difference in cost and work in the direction of benefitting the patient.

**FINANCIAL ASSISTANCE**
Nil

**CONFLICT OF INTEREST**
The authors declare no conflict of interest

**AUTHOR CONTRIBUTION**
Avanthi E has performed the studies in laboratory and recorded observations. Allen Joe Rodrigues has performed the studies in laboratory and recorded observations. Anand Koppal has analysed and interpreted the design of experiment data related to work. Abhishek Achar has analyzed and interpreted the design of experiment data related to work. Mahesh G K has contributed in drafting the manuscript

**REFERENCES**
[1] Kokiwar PR, Gupta SS, Durge PM. Prevalence of hypertension in rural community of India. J Assos Physicians India, 60, 26–9 (2012)
[2] Patel V, Chatterji S, Chisholm D, Ebrahim S, Gopalakrishna G, Mathers C. Chronic diseases and injuries in India. Lancet, 377: 413–28 (2011)
[3] Indrayan A. Epidemiology of hypertension. J Assoc Physicians India, 42(2):175–6 (1994)
[4] Mandal M, Mandal SC, Das SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 69(1):160–3 (2007)
[5] Thomas M. Rational drug use and essential drug concept. In: Prthasarthi G, Hasen KN, editors. A Textbook of Clinical Pharmacy Practice; 2004. p. 72–3.
[6] Laxminarayana K, Satish GR. Cost variation analysis of antihypertensive drugs available in Indian market: An Economic Prospective. Int J Pharm Sci Res.7(5): 2050–6 (2016)
[7] Karve A, Chattar K. Cost analysis study of oral antihypertensive agents available in Indian market. Int J Basic Clin Pharmacol, 3 (3):479-83 (2014)
[8] Limaye D. Cost-effectiveness study of Antihypertensive drugs inMumbai, India. Int J Life Sci Pharma Res, 8(1): 97–103 (2018)
[9] Roy V, Rewari S. Ambiguous drug pricing: A physicians dilemma. IJP, 30(6):404–411 (1998)
[10] Beck RK, Kumar R, Kumar V, Kachhap S. Cost analysis study of antihypertensive agents available in India. Indian J Pharm Pharmacol, 7(3):181-188 (2020)